Brevail - Oral Pharmacokinetic Study

Brevail was the subject of two university based, pharmacokinetic studies designed to determine the optimal oral dose in women.

Brevail was conceived with one goal in mind, to supplement the diet with just the right amount of lignans to achieve levels demonstrated in women with an exceptional history of breast health. We believe that success leaves clues, and when it comes to breast health it appears that there is no coincidence between women with extraordinary breast health and diets high in naturally occurring lignans.

In prior research, when healthy women were compared to women with breast related health problems, the most striking difference between the two groups was that the healthy women had higher levels of lignans in urine and plasma. While many factors can cause breast related complications, high lignan levels remained statistically significant even after all known and suspected causes for breast problems where considered. 

To establish efficacy, Brevail was the subject of two, university based, oral pharmacokinetic studies designed to supplement the diet with lignans in order to achieve urinary and plasma levels comparable to the reference group of women who exhibited an extraordinary history of breast health.

Chosen to lead and direct these studies was Dr. Kenneth Setchell, Ph.D.,  renowned lignan researcher, recognized as the father of lignans. Dr. Setchell was the first person to discover lignans in biologic fluids. Further, and as a result of his discovery, Dr. Setchell himself gave mammalian lignans their novel scientific names.   

A total of 30 women were recruited to participate in the studies.

Each woman was randomly administered one of three possible dosages of Brevail daily in a double blind fashion. After each woman completed a 7-day course with one of the dosages, Brevail supplementation was ceased until they fully purged supplemental lignans from their bodies. This cycle was repeated until all 30 women had each taken all three dosages. Urinary and blood plasma levels of lignans were tested before, during, and after each course.

The physiologic rise and eventual plateau of lignans in the body was carefully documented, as was the decline of lignans in the body after lignan supplementation was stopped.

In addition to the above study, which researched the daily ingestion of lignans in the body, a one-time bolus of lignans was also administered to carefully monitor and document the effects of Brevail in the body on an almost hourly basis.

Following the studies, the lignan profiles of all 30 women at all 3 dosages were carefully plotted and compared to the reference group of women who exhibited an extraordinary history of breast health.

These studies concluded that a supplemental dosage of 200 mg of Brevail, providing 50 mg of SDG lignan, raised lignan levels in urine and plasma comparable to the reference group of women.

The ultimate outcome of these studies is Brevail, a proactive product intended for women who wish to maintain optimal breast health.

These studies are unprecedented in the history of dietary supplements both in scope, and potential application. Brevail has set the benchmark in providing science-based evidence for the ultimate health and welfare of people everywhere.